登录 |  注册 |  忘记密码 |  公司首页
简体   繁體   English
首页 > 癌症(英文版) >Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

    加入收藏夹      点击:3     下载:1

The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well under-stood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma” in theJournal of the National Cancer Institute, providing a potential explanation for this limited beneift. We found that in mice bearing HCCs that had acquired resistance to sorafenib, tumors had switched from using angiogenesis for growth to co-opting the liver vas-culature by becoming more invasive. Accumulating evidence suggests that many human tumor types may use vessel co-option, which has profound implications for the use of anti-angiogenic agents for cancer treatment.

作 者 Elizabeth A.Kuczynski(Sunnybrook Research Institute, 2075 Bayview Avenue, S-Wing, Room S217, Toronto, 0N M4N 3M5, Canada);Robert S.Kerbel(Sunnybrook Research Institute, 2075 Bayview Avenue, S-Wing, Room S217, Toronto, 0N M4N 3M5, Canada);
刊 名 癌症(英文版)  2016年35卷12期 641-644页  美国《化学文摘》(Chemical Abstracts)收录中国科技论文统计源期刊(中国科技核心期刊)收录
关键词 Vessel co-option Non-angiogenic Resistance Sorafenib Hepatocellular carcinoma
DOI号 10.1186/s40880-016-0162-7

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他相关网站。

北京万方数据股份有限公司

万方数据电子出版社

关于我们  |   联系我们  |   网站地图  |   主要产品  |   主要服务

使用帮助  |   服务承诺  |   诚聘英才  |   友情链接  |   知识产权

客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

客服邮箱:yiyao@wanfangdata.com.cn

充值卡购卡热线:400-667-1808

互联网出版许可证 新出网证(京)字042号

互联网药品信息服务资格证书号:(京)-经营性-2011-0017

信息网络传播视听节目许可证

京公网安备11010802020237号

京ICP证010071号